C-FSZHPretzel Therapeutics
mitochondrial bioenergetics, mtDNA modulation, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FSZH
C-FSZHC-FSZHmitochondrial bioenergetics, mtDNA modulation, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
In case you aren't in a shopping mall, and you're craving a pretzel dog, Auntie Anne's has you covered in the frozen food aisle. Support the NUMBER SIX WITH CHEESE web series here: http://www.patreon.com/numbersixwithcheese We use music from: https://soundcloud.com/gwizdb https://soundcloud.com/clancyclarke/tracks https://soundcloud.com/freemusicforvlogs https://player.epidemicsound.com/ BUY OUR T-SHIRTS: http://www.numbersixwithcheese.com/merch Donating to Sean and Corey's web series: http://www.patreon.com/numbersixwithcheese Our FB: https://www.facebook.com/numbersixwithcheese/ Our mailing address: Sean Ely and Corey Wagner 3023 N. Clark St. Unit #847 Chicago, IL 60657 All our monthly Patreon patrons listed below ($3+ up) Nacho Cheese Fountain members: *HotSauceDaily *YX Flier *Masom Hamadeh *Jessica Puckett *Tai Hao Le *Hannah Elizabeth-Morris *Bill Barrett *Jon Rietz *Anjelica Jesus *Michael Srock *Michael Goodrich *Chris S Gauris *Sunny Gakhal *Alex Kalogeropoulos *Bayle
PharmaSource Podcast: Baruch Harris on Building Biotech Companies | Pretzel Therapeutics posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … of equity, a structural innovation that could reshape how pre-revenue biotechs fund pivotal trials and commercialization. The synthetic royalty deal, tied t Apogee Secures $1.3 Billion From Blackstone as Alternative Capital Reshapes Biotech Financing plocamium.com Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Asabys Partners 9,430 followers 1w Report this post On June 3rd, our co-Founder and Managing Partner, Clara Campàs Moya , will moderate … ision Ventures , with backers including SV Health Investors' Dementia Discovery Fund (DDF) , UTEC, Ono Venture Investment, and Mass General Brigham Ventures . The company plans to use the funding to advance its lead small-molecule program targeting EphB3 and to support important IND-enabling development activities. Kevin Hodgetts 🔗 Read full article link in comment #violettherapeutics #biotech #startupnews #businessnews #businessupdate #innovation 2 1 Comment Like Comment Sh … once. Seed rounds multiplied, up 35%. A handful of platforms raised at venture-fund scale. Everything in between had to justify itself harder. Moreover, landmark deals show market dynamics, including in AI drug discovery and obesity as a durable European investment theme. #ffund #funding #pharmaceutics #biotech …more 22 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 6,435 followers View Profile Follow More from this author Rare Diseas
Pretzel Therapeutics presents preclinical data supporting POLRMT as a novel target for the treatment of Metabolic Disease at ObesityWeek 2025 - Cambridge Innovation Capital Investors Back to news & insights Pretzel Therapeutics presents preclinical data supporting POLRMT as a novel target for the treatment of Metabolic Disease at ObesityWeek 2025 Back to insights Business Wire 4 Nov 2025 Inhibition of mitochondrial RNA polymerase (POLRMT) drives significant weight loss and improved metabolic markers in obese mouse models. Findings underscore the promise of targeting mitochondrial transc … rst Name Last Name Company Name (Required) Email (Required) Consent By clicking submit below, you consent to allow Cambridge Innovation Capital Limited and its subsidiaries, being Cambridge Innovation Capital Manager Limited and any future subsidiaries of either party, to store and process the personal information submitted above to provide you the content requested. Email This field is for validation purposes and should be left unchanged. PRI supports its international netwo
From ‘science fiction’ to ‘just hard’: Mitochondrial DNA editing inches closer to reality --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section New opioid painkiller has surprisingly few side effects Will community air monitoring bring 'Cancer Alley' cleaner air? Iran war threatens global helium supply The funds that fueled chemi … nucleic acids rules out many common gene-editing tools, such as the 2020 Nobel Prize–winning technique CRISPR , which uses a guide RNA to direct the editing machinery. Mitochondrial gene editing requires an all-protein crew. In humans and most other animals, each mitochondrion carries 10 or so copies of circular mitochondrial DNA (mtDNA), totaling up to thousands of these genomes per cell. They can exist as a mixture of mutant copies and normal wild-type ones, a concept call … ersity of Miami ( Hum. Mol. Genet. 2001, DOI: 10.1093/hmg/10.26.3093 ). But the application of these enzymes is quite limited. Restriction endonucleases sever DNA when they recognize certain sequences of around six base pairs. And such a short sequence has a high likelihood of appearing in the wild type too, Moraes says. “How many six-base-pairs sequences in the mitochondrial DNA do we have that’s unique?” So far, Moraes says, only one type of mitochondrial disease is amenabl … logy is still years away from clinical relevance, it has found a more immediate application in the laboratory: engineering animal models to carry mitochondrial mutations for preclinical testing. Before base editing’s emergence, there were few live models with the right mitochondrial mutations. Several early tests used animals that were engineered to carry mitochondrial mutations in the nuclear genome instead. But thanks to base editing, researchers may now have an easier shot … scientists will uncover new enzymatic possibilities. Send the reporter feedback Submit a Letter to the Editor for publication Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society Enjoyed the article? Share From ‘science fiction’ to ‘just hard’: Mitochondrial DNA editing inches closer to reality Compared with a
Small molecule rescues unstable mitochondrial enzyme --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section New opioid painkiller has surprisingly few side effects Will community air monitoring bring 'Cancer Alley' cleaner air? Iran war threatens global helium supply The funds that fueled chemistry Farm bill and Trump’s glyphosate … Braner covers the life sciences from New York City. Send the reporter feedback Submit a Letter to the Editor for publication Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society Enjoyed the article? Share Small molecule rescues unstable mitochondrial enzyme Pretzel Therapeutics’ polymerase stabilizers could treat mitochondrial DNA-based diseases cen.acs.org Advertisement More in Drug Development Editor's Picks Popular Return to top 2/3 FR
Mitochondrial drugs, with a twist: Pretzel Therapeutics launches with $72.5M in funding | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent P … nificant setbacks, falling short in a previous Phase 3 study and getting a drug application rejected by the Food and Drug Administration. Elsewhere, Mitobridge, a biotech bought by Astellas in 2017, is in clinical testing with two drugs. Vincere Biosciences is researching small molecules to improve mitochondrial quality, while Reneo Pharmaceuticals is developing drugs to treat rare genetic diseases caused by mitochondrial dysfunction. But Pretzel claims it is looking at mitoc … facility in Gothenburg, Sweden. Arch and Mubadala, a sovereign venture capital fund from the United Arab Emirates, invested $15 million apiece in the company. GV, Invus and Angelini Ventures filled out the round along with more than half a dozen other investors. Though Pretzel isn't disclosing exactly which diseases it’s targeting, its investors see a wide range of possibilities. “We’re more intrigued and excited by the hard-to-reach fruits like Alzheimer's and diabetes, whi
Top 11 Waltham Startups to Watch in 2026 Failory Interviews Blog Graveyard Products Subscribe → Download Our List of The Top 100 Accelerators & Incubators This free sheet contains 100 accelerators and incubators you can apply to today, along with information about the industries they generally invest in. Thank you! Your submission has been received! Oops! Something went wrong while submitting the form. Download The List of the 100 Highest-Valued Unicorns This free sheet contains all the information about the top 100 unicorns, including their valuation, HQ's location, founded year, nam
Breakthrough molecule offers hope for treating rare mitochondrial diseases Skip to content Menu Medical Home Life Sciences Home Become a Member Search Medical Home Life Sciences Home About Functional Food News Health A-Z Drugs Medical Devices Interviews White Papers More... MediKnowledge eBooks Posters Podcasts Videos Newsletters Health & Personal Care Contact Meet the Team Advertise Search Become a Member Top Health Categories Coronavirus Disease COVID-19 Diet & Nutrition Artificial Intelligence Allergies Alzheimer's & Dementia Arthritis & Rheumatology Breast Cancer Breast … nfidential information. Read the full Terms & Conditions . Provide Feedback Submit Cancel You might also like... × Study discovers memory switchboard that protects past knowledge
Waltham biotech Pretzel Therapeutics launches with $72.5m - The Boston Globe Skip to main content Sections Epaper Sports Red Sox Patriots Celtics Bruins High Schools Colleges Women's Sports TV & Radio Metro Weather Politics Transportation Education Cambridge & Somerville Around Mass. Investigations Obituaries Death Notices Games & Puzzles Align Crossword Mini Crossword KenKen Sudoku Word Flower Business Technology Economy Housing Real Estate Biotech The Fine Print Bold Types Politics Money, Power, Inequality Climate Spotlight Opinion Ideas Columns and Op-eds Editorials Letters
Pretzel Therapeutics: Untwisting Mitochondrial Dysfunction with Precision | Jesse Landry posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or … like a prayer than a pitch, Pretzel just pulled in fresh backing from The Mito Fund, the venture arm of the United Mitochondrial Disease Foundation . And while the amount is hush-hush, the signal is loud: If you're working on #POLG disorders or #mtDNA depletion syndromes and your lead compound is already in Phase1, the right people take notice. Founded in 2019 by three heavyweights in #mitochondrialbiology , Claes Gustafsson , Michal Minczuk , and Nils-Goran Larsson , Pretze … ing a global population of ~33,000 with virtually no approved options. The Mito Fund didn't just write a check. They validated a vision, one backed by a scientific advisory board featuring Nobel winners like Sir John Walker and Roger Kornberg. That's not window dressing. That's architectural credibility. Between their Waltham HQ and their Swedish R&D engine, Pretzel is running a cross-Atlantic model that fuses U.S. clinical scale with Nordic academic firepower. It's lean, … ristian and his team, with support from visionary investors at Novartis Venture Fund and OrbiMed realized that this wasn’t just about #fibrosis . The same approach could unlock treatments for #oncology , monogenic blood disorders, and even autoimmune diseases. The insight? 👉 Transition from a product to a platform. 👉 Build something that could serve multiple therapeutic frontiers, not just one. But with big opportunities come big debates. Investors pushed for oncology the f … are how his team is bridging the gap between research innovation and industrial application. With experience in tech valorisation and life science commercialization, Tony brings unique insights into how robust analytics can accelerate cell and gene therapy development. 🔬 Don’t miss this session to see how cutting-edge analytics are transforming
The Mito Fund Makes Investment in Pretzel Therapeutics – The Mito Fund: UMDF's Venture Philanthropy Initiative Skip to content Spark a Conversation with The Mito Fund UMDF.org Home About How it Works Portfolio Founders Circle Home About How it Works Portfolio Founders Circle Main Menu Home About How it Works Portfolio Founders Circle The Mito Fund Announces Investment in Pretzel Therapeutics The Mito Fund Announces Investment in Pretzel Therapeutics Company working on novel treatments for POLG-related mitochondrial diseases The United Mitochondrial Disease Foundation’s (UMDF) ventur … ed Mitochondrial Disease Foundation’s (UMDF) venture philanthropy arm, The Mito Fund, has invested in Pretzel Therapeutics, a Massachusetts-based company with research facilities in Mölndal , Sweden, focused on harnessing cellular energetics to modulate disease processes and improve survival, function and quality of life for a breadth of conditions. PX578, the lead development program in Pretzel’s bioenergetics portfolio, recently entered Phase 1 clinical development in the U … icer Dr. Philip Yeske. “We are honored to receive this investment from The Mito Fund, whose commitment to improving the lives of patients living with mitochondrial disease aligns deeply with our mission,” said Gabriel Martinez, Ph.D., Chief Scientific Officer and Co-Founder of Pretzel Therapeutics. “This funding not only validates the promise of our scientific approach, but also supports development of PX578, the lead therapeutic in our energetics restoration franchise, with … romes and broader degenerative diseases.” Like all investments made by The Mito Fund, the Pretzel Therapeutics consideration went through a rigorous review process by UMDF’s Venture Philanthropy Investment Committee, an advisory group consisting of world-class experts in the areas of mitochondrial disease, pharmaceutical development, and private equity investments. After receiving the committee’s recommendation, the investment was then approved by UMDF’s full Board of Trustee … orward to deepening the relationship with Pretzel.” Other companies in The Mito Fund portfolio include: Napigen Therapeutics, a company that aims to harness the potential of mitochondria to impact human healthcare with its unique organelle genome editing tools. Pierrepont Therapeutics, a company focused on advancing to the clinic a proprietary in
MitoWorld BETA Back to MitoWorld MitoWorld™ Welcome to the world of mitochondria Patients and Clinics Patient Orgs. Clinics MitoGuide Research and Industry Papers MitoPapers MitoRxiv Literature Highlights Collections Investigators Industry Funding Agencies Resources Working Groups Media and Events Events Media Books MitoMedia MitoBlog Mito-Cancer Conference Coverage MitoCast UMDF Beyond the Disease MitoNews MitoMap MitoGuide MitoPoster About Us Mission & Team Steering Committee Scientific Advisors Industry Advisors Medical Advisors Partners Services Downloads Topic Home / Michal Min … received numerous awards and personal fellowships, including the Prime Minister Prize for his PhD thesis, Award of the Foundation for Polish Science , EMBO and FEBS Fellowships, served as an editor of several journals and books and organised a number of scientific conferences. More recently, Michal has co-founded Pretzel Therapeutics , a start-up biotechnology company that focuses on the development of therapies to treat unmet needs in diseases driven by mitochondrial dysfunc
Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion » Pretzel Therapeutics Skip to Main Content Menu Close About Us Science & Pipeline Publications and Presentations Join Us News Contact Us Press Releases Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion April 9, 2025 Restores function to mutant mitochondri
Jay Parrish, Ph.D. - ARCH Venture Partners You are using an outdated browser. Please upgrade your browser to improve your experience. Toggle navigation About Portfolio Initiatives Strategic Partnerships Team News Contact > Jay Parrish, Ph.D. Venture Partner Dr. Jay Parrish is a Venture Partner at ARCH Venture Partners and Chairman of Pretzel Therapeutics, a company focused on developing first-in-class therapeutics addressing mitochondrial dysfunction. Previously, he was co-founder and Chief Business Officer of Vir Biotechnology, a company focused on infectious disease. As Vir’s first employee, … nic Chemistry from the University of South Florida. He completed a Postdoctoral Fellowship at the Scripps Research Institute and received an M.B.A. from U.C. Berkeley’s Haas School of Business. ALL Partners, Associates, Affiliates COMPANY About Portfolio Initiatives Strategic Partnerships Team News Contact LOCATIONS Chicago, IL Seattle, WA ©2026 Arch Venture Partners Terms of Use Privacy Policy CONNECT
Small molecule rescues unstable mitochondrial enzyme | Pretzel Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agree
Pretzel Therapeutics Reveals Novel mtDNA Deficiency Syndrome Drugs | Inside Precision Medicine clinicalomicsprowebdirectory Facebook Linkedin Twitter News Topics Informatics Molecular Dx Patient Care Oncology Precision Medicine Translational Research Magazine Browse Issues Subscribe Subscribe Get Inside Precision Medicine Magazine Get Inside Precision Medicine eNewsletters Multimedia Webinars Summits Podcasts Videos Inside Precision Medicine Live Learning Labs eBooks Search Facebook Linkedin Twitter Sign in Welcome! Log into your account your username your password Forgot your password? Get he
Pretzel Therapeutics launches to advance mitochondria-based therapies --> Advertisement Skip to main content ACS ACS Publications C&EN CAS Jobs Main menu News Topics Newsletter Podcasts Explore Explore Skip Explore section Features Perspectives Interviews ACS News Graphics Chempics Games Newscripts Webinars Whitepapers & E-books Highlights Highlights Skip Highlights section New opioid painkiller has surprisingly few side effects Will community air monitoring bring 'Cancer Alley' cleaner air? Iran war threatens global helium supply The funds that fueled chemistry Farm bill and T … and is not disclosing any of its targets right now. Send the reporter feedback Submit a Letter to the Editor for publication Chemical & Engineering News ISSN 0009-2347 Copyright © 2026 American Chemical Society Advertisement Enjoyed the article? Share Pretzel Therapeutics launches to advance mitochondria-based therapies Among the tools in the company’s arsenal is gene editing of mitochondrial DNA cen.acs.org Advertisement More in Start-ups Editor's Picks Popular Return t
Pretzel Therapeutics Reveals Novel mtDNA Deficiency Syndrome Drugs | Pretzel Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedI
Claes Gustafsson M.D., Ph.D. - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Claes Gustafsson M.D., Ph.D. Co-Founder at Pretzel Therapeutics Claes Gustafsson M.D., Ph.D. 's Executive Work History Current Co-Founder , Co-Founder Equilar on 05/20/2026 Pretzel Therapeutics Past To view Claes Gustafsson M.D., Ph.D.'s co
Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer — GU Ventures Mission Offer Portfolio For investors Team Job openings News + More Back Investment Opportunities Vasa Angels Back GU Ventures 30 Board of directors Corporate governance Contact Initiatives FDS Mission Offer Portfolio For investors Investment Opportunities Vasa Angels Team Job openings News + More GU Ventures 30 Board of directors Corporate governance Contact Initiatives FDS Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies .................... … al biology at Stanford University School of Medicine and recipient of the Nobel Prize in Chemistry (2006) About Pretzel Therapeutics Pretzel Therapeutics is a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies. Pretzel was founded by leading academic experts in mitochondrial biology and is backed by a world-class investor syndicate. The company is headquartered in Waltham, MA and has research facilities in Gothenburg, … Follow us on MyNewsDesk Facebook LinkedIn X Instagram Organisations that fund GU Ventures and our initiatives: GDPR
Congratulations to Professor Claes Gustafsson, one of the scientific founders of our portfolio company Pretzel Therapeutics on this well deserved recognition. | Eir Ventures LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject
Pretzel Therapeutics Announces Publication in Nature unveiling discovery of novel small molecule activators for the treatment of POLG disorders and other conditions related to mtDNA depletion »… | Eir Ventures LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any t
Pretzel Therapeutics Launches as a new Start Up | MRC Mitochondrial Biology Unit skip to content Study at Cambridge About the University Research at Cambridge Search site Home Study at Cambridge Undergraduate Undergraduate courses Applying Events and open days Fees and finance Postgraduate Postgraduate courses How to apply Postgraduate events Fees and funding International students Continuing education Executive and professional education Courses in education About the University How the University and Colleges work Term dates and calendars History Map Visiting the University Annual reports Eq
Industry Collaboration: Pretzel Therapeutics and SciLifeLab Cryo-EM platform to advance mitochondrial drug discovery | SciLifeLab LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue … on $4.5B Virginia-based API plant 💼 Ascenta Capital announced inaguraul $325M fund focused on platform biotech ✅ ONO PHARMACEUTICAL CO., LTD. + Bristol Myers Squibb 's EP4 antagonist touts positive Ph2 data in gastric cancer 🤖 AstraZeneca + Turbine partner on ADC discovery via experimental virtualization at scale 👁️ AviadoBio in-licenses rare eye disease gene therapy from China's UgeneX Therapeutics Co., Ltd. for up to $413M 🫁 Expedition Therapeutics raises $165M Series
Pretzel Therapeutics launches with focus on mitochondrial biology | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape
MitoWorld BETA Back to MitoWorld MitoWorld™ Welcome to the world of mitochondria Patients and Clinics Patient Orgs. Clinics MitoGuide Research and Industry Papers MitoPapers MitoRxiv Literature Highlights Collections Investigators Industry Funding Agencies Resources Working Groups Media and Events Events Media Books MitoMedia MitoBlog Mito-Cancer Conference Coverage MitoCast UMDF Beyond the Disease MitoNews MitoMap MitoGuide MitoPoster About Us Mission & Team Steering Committee Scientific Advisors Industry Advisors Medical Advisors Partners Services Downloads Topic Mitochondrial Fro … mechanisms may influence these conditions. To this end, we have been awarded a grant from Parkinson’s-UK, a leading charity supporting research, to study our mechanisms in Parkinson’s disease. Gary C. Howard is a science editor and writer. He is the author of The Biology of Death and The Biology of Us , both published by Oxford University Press. He received a PhD in biological sciences from Carnegie Mellon University and completed fellowships at Harvard and Johns Hopkins. --
Pretzel Therapeutics | | The Pharmaletter Tuesday 9 June 2026 About Contact Login VC & Investment M&A AI Podcasts News Pharmaceutical News Biotechnology News Generics News Biosimilars news In Brief Legal Company Pages In The Boardroom Insights Analysis Special Report Interviews Expert View From Our Correspondent One To Watch Companies Digital Pharma Pharma Leaders Regulatory FDA EMA Pricing, Reimbursement and Access Regulation Government Affairs Trump Administration Therapy Areas Dermatologicals Oncology Neurological Rare Diseases Hematology Cardio Vascular Diabetes Cell And Gene Thera
#jpm2026 #biotech #healthcareinnovation #lifesciences | Pretzel Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agre
Pretzel Therapeutics (SE) - [LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal Zum Inhalt News People Events Deals Organisations Newsletter About us Contact Top News Roche and Nurix: up to $2.3b Agreement for BTK Degrader Fusix Biotech & Recipharm Advance Oncolytic Virus Platform Merck Appoints Two Life Sciences Leadership Team Members Ona Therapeutics Raises $86.6mSeries B to Advance ADCs DaltonTx Launches Platform and Partners with Sygnature Olix Pharma Secures KRW110b Investment from BOLD and Weiss Lundbeck & Cradle Partner for AI-based Brain Disorder R&D Genovis Acquire … ger: £15m Biopharma Maintenance Contract in Scotland » More News! » Submit your News! Upcoming Events IHMC 2026 Seoul (International Human Microbiome Consortium Congress 2026) HPLC 2026 (HPLC2026) Indianapolis Goldman Sachs Annual Global Healthcare Conference 2026 Miami World ADC South Korea 2026 Seoul bio:cap Investival 2026 Berlin (BioCap 2026) Swiss Medtech Day 2026 Bern Bio Innovations Europe 2026 The Hague Citi European CEO Healthcare Conference 2026 London E … Day 2026 Martinsried (Munich) ISSCR 2026 Montréal » More Events! » Submit your Event! Management Appointments Endress+Hauser Appoints Christian Mäder as Future CFO Orlando Oliveira Succeeds Dario Eklund as CEO of Santhera Clara Sattler de Sousa e Brito Joins Merck (DE) from Philips Evotec Nominates Dieter Weinand as Supervisory Board Chair Santhera Appoints Marc Clausse as Chief Commercial Officer Fujifilm Biotechnologies Appoints Christiane Bardroff as CBO Camil … n Bulling Joins ProBioGen as Chief Operating Officer » More News! » Submit your News! Financings & Acquisitions Ona Therapeutics Raises $86.6mSeries B to Advance ADCs Olix Pharma Secures KRW110b Investment from BOLD and Weiss T-Curx GmbH Acquires Pantherna Therapeutics GmbH Genovis Acquires KPL ApS for DKK30.5m Upfront plus Earn-outs Lilly to Acquire LimmaTech Biologics for up to $780m in Cash InSphero Acquires PhenoVista Biosciences to Expand in US Lauxera Capita … henoVista Biosciences to Expand in US Lauxera Capital Partners Closes Growth II Fund at €520m Metis TechBio: $270m IPO at Hong Kong Stock Exchange NanoStruct Closes €2.6m Seed Round Led by HTGF et al. Roche to Acquire PathAI for up to $1.05b » More News! » Submit your News! Collaborations & Licensing Roche and Nurix: up to $2.3b Agree
--> Life Extension News Archive Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immort … novia powers up mitochondrial medicine Longevity Technology - 01-Sep-2025 $350K grant fuels Minovia’s biomarker work, as early trials show promising patient gains Why turtles rarely get cancer Oxford Academic (OUP Academic) - 01-Sep-2025 Research shows turtles’ unique biology helps protect them from tumours despite long lifespans Rapamycin tops NIH review of anti-aging drugs UT Health San Antonio - 28-Aug-2025 Rapamycin extended mouse lifespan by up to 28%, even when given in … onger or weaker, offering new options for healing and repair Aubrai launches to fund longevity science with AI and blockchain CoinDesk - 25-Aug-2025 New DeSci platform uses tokens and AI to speed breakthroughs in ageing research World-first lab breakthrough creates living human skin Interesting Engineering - 22-Aug-2025 New model could transform treatments for burns, wounds, and chronic skin disorders AI-powered proteins unlock faster stem cell breakthroughs OpenAI - 22-Aug-2 … 40 million to support longevity research Longevity Technology - 18-Jul-2025 The fund bridges East-West collaboration and acts quickly using its own capital Brain activity sheds light on why we persist or give up when mentally tired Johns Hopkins Medicine - 17-Jul-2025 Study links two brain areas to cognitive fatigue and motivation during demanding mental tasks Long-term obesity makes young adults biologically older Live Forever Club - 16-Jul-2025 Staying healthy young can kee … diterranean countries age faster than those in northern and western Europe Mito Fund invests in Pretzel Therapeutics for mitochondrial disease therapies Longevity Technology - 15-Jul-2025 New investment fuels development of therapies targeting mtDNA-related energy disorders Iron overload: how aging muscles rust from within UW School of Medicine a
--> Investments News Archive Medical Technology 3D Printing AI in Healthcare Assistive Technology Digital Health Digital Modeling Laboratory Automation Nanotechnology in Healthcare Precision Medicine Robotic Surgery Synthetic Biology Health Antibiotic Resistance Big Pharma Cancer Diabetes Heart Disease Mental Health Musculoskeletal System Respiratory Disease Stroke Augmentation Artificial Organs Biohacking Brain Interface Exoskeleton Nootropics Prostheses Vision Life Extension Aging Research Anti-Aging Biological Age Calorie Restriction Cryonics Ethics Fountains of Youth Gene Therapy Immortal … novia powers up mitochondrial medicine Longevity Technology - 01-Sep-2025 $350K grant fuels Minovia’s biomarker work, as early trials show promising patient gains Debut raises $20M to pioneer AI-driven skin longevity ingredients Longevity Technology - 28-Aug-2025 Startup uses AI to explore billions of molecules for next-gen skincare innovation Aubrai launches to fund longevity science with AI and blockchain CoinDesk - 25-Aug-2025 New DeSci platform uses tokens and AI to speed … 40 million to support longevity research Longevity Technology - 18-Jul-2025 The fund bridges East-West collaboration and acts quickly using its own capital Synchron challenges Neuralink with minimally invasive brain implant PC MAG - 16-Jul-2025 Stentrode lets users control devices with thoughts—implanted via blood vessels, not surgery Mito Fund invests in Pretzel Therapeutics for mitochondrial disease therapies Longevity Technology - 15-Jul-2025 New investment fuels developme … er 1,000 global contenders, the selected teams are one step closer to the $101M prize Hundred health acquires BellSant to supercharge AI longevity platform strapline: Longevity Technology - 08-May-2025 AI-driven health platform gears up for launch with cutting-edge longevity data NewLimit secures $130m to accelerate epigenetic reprogramming for longevity Longevity Technology - 06-May-2025 The biotech company aims to target the root causes of ageing to develop therapies to ext … wer a new era of brain-computer interaction Europe’s first 100m consumer health fund targets proactive care revolution Longevity Technology - 18-Feb-2025 naturalX backs startups reshaping wellness and prevention Mair Therapeutics targets Parkinson’s with AI-driven drug discovery Longevity Technology - 17-Feb-2025 The Dutch startup is using ion ch
Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise » Pretzel Therapeutics Skip to Main Content Menu Close About Us Science & Pipeline Publications and Presentations Join Us News Contact Us Press Releases Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise April 3, 2025 First-in-class approach to targeting mitochondrial DNA polymerase (POLG) with disease modifying potential across mitochondrial DNA depletion syndromes (MDDS) a … ede disease progression and severity across high unmet need indications Awarded grant from Parkinson’s UK to evaluate POLG activation mechanisms in Parkinson’s disease models WALTHAM, Mass. – April 3, 2025 – Pretzel Therapeutics, a leader in harnessing cellular energetics to develop novel treatments for a range of conditions spanning neurological, muscular atrophies, metabolic and rare disease, today announced that it has initiated recruitment in a Phase 1 clinical study of P … ess in the months to come.” The company also announced that it has been awarded grant funding from Parkinson’s UK to support evaluation of Pretzel’s POLG activation mechanism in Parkinson’s disease models in collaboration with Dr. Roberta Filograna’s lab at the Karolinska Institute, Stockholm, Sweden. “We’re excited to be funding Pretzel Therapeutics to take early but important steps in the development of a compound that has potential for the treatment of Parkinson’s. T
Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies » Pretzel Therapeutics Skip to Main Content Menu Close About Us Science & Pipeline Publications and Presentations Join Us News Contact Us Press Releases Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies September 12, 2022 Company to leverage expertise in mitochondrial biology to advance novel treatments for both rare and common diseases Pretzel founded by leading academic experts in mitochondrial biology and backed by world-class … al biology at Stanford University School of Medicine and recipient of the Nobel Prize in Chemistry (2006) About Pretzel Therapeutics Pretzel Therapeutics is a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies. Pretzel was founded by leading academic experts in mitochondrial biology and is backed by a world-class investor syndicate. The company is headquartered in Waltham, MA and has research facilities in Gothenburg,
Pretzel Therapeutics Skip to Main Content Menu Close About Us Science & Pipeline Publications and Presentations Join Us News Contact Us Welcome To A New Paradigm In Bioenergetics We are dedicated to developing life-changing medicines with a broad pipeline of first-in-class treatments addressing novel targets within the mitochondria, the primary organelles responsible for producing and regulating cellular energy. By harnessing cellular energetics, we are ushering in a new treatment paradigm for a rare and common conditions. A Vast Opportunity For Therapeutic Innovation We are harnessing ce
About Us » Pretzel Therapeutics Skip to Main Content Menu Close About Us Science & Pipeline Publications and Presentations Join Us News Contact Us About Us Our team brings together unparalleled expertise in bioenergetics Pretzel was founded by some of the world’s foremost researchers in the field of bioenergetics and mitochondrial DNA function and is led by accomplished experts in drug discovery, drug development and commercialization. This deep expertise combined with an innovative scientific approach makes Pretzel well-positioned to tackle the underlying drivers for a wide range of … g of ATP that each of us makes daily to sustain our lives. This work led to the award of the Nobel Prize in Chemistry in 1997. In 1998, John was appointed Director of the MRC Dunn Human Nutrition Unit in Cambridge, which became the MRC Mitochondrial Biology Unit in 2008. In 1999, he was knighted for his services to Science. He is a Fellow of the Royal Society, and in 2012, he received its Copley Medal, the UK’s highest scientific accolade. He is also a Fellow of the Academy o … hemistry from the University of Bristol, UK. Rebekah completed her postdoctoral fellowship at Chalmers University in Sweden. Michal Minczuk, Ph.D. Co-Founder View Bio Close Michal Minczuk, Ph.D. Co-Founder Michal Minczuk is a program leader and MRC investigator at the MRC Mitochondrial Biology Unit, University of Cambridge, and an expert in mitochondrial genome engineering with more than 20 years of experience in biotechnology. At Cambridge, Michal leads the Mitochondrial Gen … ntific understanding of eukaryotic transcription, for which he earned the Nobel Prize in Chemistry in 2006. Roger was elected to the National Academy of Sciences in 1993. He has received many awards, including the Welch prize (2001), the highest award in chemistry in the United States, and the Leopold Mayer Prize (2002), the highest award in biomedical sciences of the French Academy of Sciences. Roger holds a B.A. in chemistry from Harvard University and a Ph.D. in chemistry … . Prior to joining ARCH, Kristina was an Associate with the Novartis BioVenture Fund in San Diego. As an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development where she helped create numerous companies as spinouts from GNF. Kristina holds an MBA
Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Dea … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Pretzel Therapeutics Initiates Phase 1 Clinical Study Evaluating PX578, Lead Therapeutic in its Bioenergetics Restoration Franchise April 3, 2025 | 3 min read Twitter LinkedIn Facebook Email Print - First-in-class approach to targeting mitochondrial DNA polymerase (POLG) with disease modifying potential a … disease progression and severity across high unmet need indications - - Awarded grant from Parkinson’s UK to evaluate POLG activation mechanisms in Parkinson’s disease models - WALTHAM, Mass.--(BUSINESS WIRE)-- #pipeline --Pretzel Therapeutics, a leader in harnessing cellular energetics to develop novel treatments for a range of conditions spanning neurological, muscular atrophies, metabolic and rare disease, today announced that it has initiated recruitment in a Phase 1 clin … ess in the months to come.” The company also announced that it has been awarded grant funding from Parkinson’s UK to support evaluation of Pretzel’s POLG activation mechanism in Parkinson's disease models in collaboration with Dr. Roberta Filograna’s lab at the Karolinska Institute, Stockholm, Sweden. “We’re excited to be funding Pretzel Therapeutics to take early but important steps in the development of a compound that has potential for the treatment of Parkinson’s. Targeti … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee
Pretzel Therapeutics Strengthens Leadership with Appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Jo … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Pretzel Therapeutics Strengthens Leadership with Appointment of Ashish Dugar, Ph.D., MBA as Chief Development Officer September 4, 2025 | 4 min read Twitter LinkedIn Facebook Email Print - Veteran biotech leader from Dyne, Sarepta, Intra-Cellular, Roche and Pfizer joins Pretzel to accelerate first-in-clas … al Institutes of Health. He completed a pharmacoeconomics and outcomes research fellowship at the University of Michigan School of Public Health, earned an MBA from The Pennsylvania State University and a PhD in pharmacology from The Pennsylvania State University College of Medicine. About Pretzel Therapeutics Pretzel Therapeutics is dedicated to developing life-changing medicines with a broad pipeline of first-in-class treatments addressing novel targets within the mitochond … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Mass. biotech Pretzel Therapeutics launches with $72.5 million Skip to Main Content Cancer HHS Obesity Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home News Latest STAT10 Business Biotech Pharma Health Tech Health Insurance Hospitals Medical Devices Washington Policy … Boston Globe [email protected] @RLCscienceboss Tags biotechnology STAT+ To submit a correction request, please visit our Contact Us page . Trending GSK to buy Nuvalent, maker of targeted cancer drugs,… GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B Pharmalittle: We’re reading about Lilly and Pfizer obesity drug… Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more What stripping
Pretzel Therapeutics Presents Preclinical Data Supporting POLRMT as a Novel Target for the Treatment of Metabolic Disease at ObesityWeek 2025 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufac … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Pretzel Therapeutics Presents Preclinical Data Supporting POLRMT as a Novel Target for the Treatment of Metabolic Disease at ObesityWeek 2025 November 4, 2025 | 4 min read Twitter LinkedIn Facebook Email Print Inhibition of mitochondrial RNA polymerase (POLRMT) drives significant weight loss and improved … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Pretzel Therapeutics Announces Publication in Nature Unveiling Discovery of Novel Small Molecule Activators for the Treatment of POLG Disorders and Other Conditions Related to mtDNA Depletion - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSC … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Pretzel Therapeutics Announces Publication in Nature Unveiling Discovery of Novel Small Molecule Activators for the Treatment of POLG Disorders and Other Conditions Related to mtDNA Depletion April 10, 2025 | 3 min read Twitter LinkedIn Facebook Email Print - Restores function to mutant mitochondrial DNA … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Press Releases Pretzel Therapeutics Presents Preclinical Data on PX578 at MDA 2026, Further Supporting Clinical Advancement in Individuals Living with POLG Disease March 12, 2026 | 4 min read Twitter LinkedIn Facebook Email Print Preclinical data across multiple disease models demonstrate that PX578 increases mtDNA leve … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell a … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Pretzel Therapeutics Launches With $72.5 Million Series A Financing to Pioneer Mitochondrial Therapies September 12, 2022 | 6 min read Twitter LinkedIn Facebook Email Print Pretzel Therapeutics, a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies, laun … al biology at Stanford University School of Medicine and recipient of the Nobel Prize in Chemistry (2006) About Pretzel Therapeutics Pretzel Therapeutics is a biotechnology company harnessing the intricacies of mitochondrial biology to develop groundbreaking therapies. Pretzel was founded by leading academic experts in mitochondrial biology and is backed by a world-class investor syndicate. The company is headquartered in Waltham, MA and has research facilities in Gothenburg, … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Pretzel Therapeutics Launches with $72M to Advance Mitochondrial Therapies - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opini … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Pretzel Therapeutics Launches with $72M to Advance Mitochondrial Therapies September 12, 2022 | 3 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print Pretzel Therapeutics launched Monday with $72.5 million in Series A financing to develop novel, mitochondria-based th … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee Armstrong FDA Busy FDA gives rare disease sector complementary pathways, unanswered questions June 8, 2026 · 8 min … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin